An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age.

Trial Profile

An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Apr 2013 Accrual to date is 105% according to United Kingdom Clinical Research Network.
    • 31 May 2012 Planned end date changed from 1 Jan 2012 to 20 Apr 2012 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top